
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
Exom Group launched the Caravaggio Study, a Cloud & Mobile Clinical Trial, that will randomize around 1, 200 patients from 160 clinical sites spanning Europe, Israel, and the U.S.
Read the full release






